<DOC>
	<DOCNO>NCT00656097</DOCNO>
	<brief_summary>The aim study evaluate safety monoclonal antibody cocktail CL184 combination rabies vaccine compare human rabies immune globulin ( HRIG ) placebo combination rabies vaccine healthy adult subject .</brief_summary>
	<brief_title>A Randomized Phase II Trial Compare Safety Neutralizing Activity CL184 Combination With Rabies Vaccine vs. HRIG Placebo Combination With Rabies Vaccine Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Rabies</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects free obvious healthproblems stable condition Male female subject age ≥19 ≤65 year BMI ≥18 ≤30 kg/m2 Prior history active passive rabies immunization Clinically significant acute illness infection within 2 week first dose base clinical judgment investigator History and/or family history clinically significant immunodeficiency autoimmune disease Any clinically significant history know suspected anaphylaxis hypersensitivity reaction Chronic administration immunosuppressant immunemodifying drug within 6 month first dose investigational medicinal product</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Rabies post-exposure prophylaxis</keyword>
</DOC>